Lee, Jaeick et al. published their research in Therapeutic Drug Monitoring in 2005 | CAS: 69256-17-3

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Application of 69256-17-3

Rapid Quantitative Determination of L-FMAU-TP from Human Peripheral-Blood Mononuclear Cells of Hepatitis B Virus-Infected Patients Treated with L-FMAU by Ion-Pairing, Reverse-Phase, Liquid Chromatography/Electrospray Tandem Mass Spectrometry was written by Lee, Jaeick; Yoo, Byung-Chul; Lee, Hyo-Suk; Yoo, Hee-Won; Yoo, Hye-Hyun; Kang, Min Jung; Kim, Dong-Hyun. And the article was included in Therapeutic Drug Monitoring in 2005.Application of 69256-17-3 The following contents are mentioned in the article:

The purpose of this study was to develop an anal. method for the determination of 2′-fluoro-5-methyl-β-l-arabinofuranosyl uracil triphosphate (L-FMAU-TP) in human peripheral blood mononuclear cells (PBMCs), and its application in the determination of cellular levels of L-FMAU-TP in PBMCs isolated from patients treated with 2′-fluoro-5-methyl-β-l-arabinofuranosyl uracil (L-FMAU). An ion-pairing liquid chromatog. (IPC) method, coupled with neg. ion electrospray ionization tandem mass spectrometry (ESI-MS/MS), was developed for the accurate and repeatable detection of L-FMAU-TP, with a limit of detection of 1.6 pmol/106 cells. The calibration curve for L-FMAU-TP was linear over the concentration range 1.6 to 80 pmol/106 cells. The intra- and inter-day precision was lower than 11.2%, and the accuracy was between 97.1 and 106.9%. When applied to the determination of L-FMAU-TP in PBMCs isolated from HBV-infected patients undergoing L-FMAU treatment, the levels reached a steady state concentration 4 wk after daily single oral administration of 20 mg L-FMAU, and these levels were maintained for up to 12 wk, but then decreased 12 wk after drug cessation. The terminal half-life of L-FMAU-TP in PBMCs after drug cessation was estimated to be 15.6 days. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Application of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Application of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3